BioNTech expands ADC deal with DualityBio; Gracell and IO Biotech get private placements from a slew of investors

BioN­Tech is forg­ing a big­ger al­liance with its an­ti­body-drug con­ju­gate part­ner Du­al­i­ty­Bio, adding an­oth­er ADC to their bil­lion-dol­lar union.

Du­al­i­ty­Bio an­nounced the strate­gic ex­pan­sion on Mon­day, say­ing that the Shang­hai biotech will re­ceive undis­closed up­front pay­ments, along with ad­di­tion­al mile­stones and roy­al­ties from BioN­Tech for DB-1305, which is be­ing test­ed in a Phase I/II sol­id tu­mor tri­al.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.